Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis [0.03%]
通过全转录组分析揭示透明细胞肾细胞癌中不同的空间景观
J I López,M F Hogan,B Sutton et al.
J I López et al.
Background: Clear-cell renal cell carcinoma (ccRCC) is the most common and aggressive form of renal cancer and a paradigm of inter- and intratumor heterogeneity. We carried out an exploratory digital spatial profiling of ...
Engineering approaches for innate immune-mediated tumor microenvironment remodeling [0.03%]
用于改造先天免疫介导的肿瘤微环境的工程方法
G I Kane,C F Lusi,M L Brassil et al.
G I Kane et al.
Cancer immunotherapy offers transformative promise particularly for the treatment of lethal cancers, since a correctly trained immune system can comprehensively orchestrate tumor clearance with no need for continued therapeutic intervention...
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit [0.03%]
学术医药中先进治疗药物研发的基础及GMP模拟单元的作用
I Johanna,A Daudeij,F Devina et al.
I Johanna et al.
Following successes of authorized chimeric antigen receptor T-cell products being commercially marketed in the United States and European Union, product development of T-cell-based cancer immunotherapy consisting of cell-based advanced ther...
M Anastasiou,A Kyriazoglou,I Kotsantis et al.
M Anastasiou et al.
Sarcomas are tumors that originate from mesenchymal cells. The variety of sarcomas' response to chemotherapy and the wide range of prognosis reflect their heterogeneity. In order to improve the rates of response, the research has been orien...
Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma [0.03%]
人多能干细胞来源的嵌合抗原受体巨噬细胞在胶质母细胞瘤中的应用研究
G Jin,Y Chang,X Bao
G Jin
Background: Glioblastoma (GBM) is an aggressive brain tumor giving a poor prognosis with the current treatment options. The advent of chimeric antigen receptor (CAR) T-cell therapy revolutionized the field of immunotherap...
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors [0.03%]
PD-1和PD-L1基因单核苷酸变异体在预测晚期黑色素瘤患者接受PD-1抑制剂治疗的预后和疗效中的作用
A Boutros,R Carosio,D Campanella et al.
A Boutros et al.
Background: Despite having revolutionized the treatment paradigm for advanced melanoma, not all patients benefit from immune checkpoint inhibitor therapy. To date, there are no predictive biomarkers for response or the oc...
Corrigendum to "Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies": [Immuno-Oncology and Technology 10 (2023) 100394] [0.03%]
“利用理性工程改进腺苷脱氨酶2酶以增强T细胞治疗的效力”的勘误：[免疫肿瘤学和技术 10(2023) 100394]
J R Cox,M Jennings,C Lenahan et al.
J R Cox et al.
[This corrects the article DOI: 10.1016/j.iotech.2023.100394.]. © 2023 European Society for Medical Oncology. Published by Elsevier Ltd. All rights rese...
Published Erratum
Immuno-oncology technology. 2023 Oct 17:20:100410. DOI:10.1016/j.iotech.2023.100410 2023
CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy [0.03%]
2023年国际免疫治疗大会（CIMT）会议纪要——第20届癌症免疫治疗协会年度会议
J Dallmann,J Freitag,C Jung et al.
J Dallmann et al.
The Association for Cancer Immunotherapy (CIMT) celebrated the 20th anniversary of the CIMT Annual Meeting. CIMT2023 was held 3-5 May 2023 in Mainz, Germany. 1051 academic and clinical professionals from over 30 countries attended the meeti...
Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma [0.03%]
基于检点抑制剂治疗临床反应的晚期黑色素瘤外周免疫细胞监督分类聚集研究
A H Kverneland,S U Thorsen,J S Granhøj et al.
A H Kverneland et al.
Background and purpose: Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not respond well to therapy and there are no b...
Y Wang,H Wang
Y Wang
Immunotherapy that aims to boost the body's immune responses against pathogens or diseased cells has achieved significant progress for treating different diseases over the past several decades, especially with the success of checkpoint bloc...